CRG Appoints Adam Whitehead as Vice President of Investor Relations

04:06 EDT 19 Oct 2016 | PR Newswire

HOUSTON, Oct. 19, 2016 /PRNewswire/ -- CRG, a global healthcare-focused investment firm supporting innovative healthcare companies, announced today the appointment of Adam Whitehead as Vice President of Investor Relations in the firm's Boulder office. Mr. Whitehead will help build and manage relationships with CRG's limited partners and expand the firm's investor relations strategy. Mr. Whitehead will report to Mike Weinmann, Managing Director at CRG.

Mr. Whitehead brings to CRG more than 10 years of experience in asset allocation, manager due diligence and fundraising, and established relationships with institutional investors. Previously, Mr. Whitehead spent six years as a senior investment analyst at Crestone Capital Advisors, a large multi-family office for ultra-high net worth entrepreneurs and executives. He also served as Vice President of Research for Sovereign Wealth Management. In addition, Mr. Whitehead served as Vice President of Research for Quantitative Equity Systems; Director of Research at The Bornhoft Group; and Principal and Director of Trading and Research at Warwick Capital Management. He began his investment career as a Proprietary Trader and Asset/Liability Modeler at Branch Banking & Trust.

Mr. Whitehead graduated from Saint Andrews Presbyterian College, magna cum laude, in Laurinburg, North Carolina with a double major in business (emphasis in finance and accounting).

"Adam brings to CRG deep knowledge of the alternative investment landscape and a strong book of contacts to continue our rapid growth," said Nate Hukill, President of CRG. "This exciting addition will help us better service our limited partners and expand on relationships with institutional investors that allocate to private capital investment strategies."

About CRG

Founded in 2003, CRG (previously known as Capital Royalty L.P.) is a healthcare-focused investment firm that delivers pioneering growth capital financing solutions to the global healthcare industry. With nearly $3.0 billion of assets under management across 42 healthcare investments, CRG provides growth capital to healthcare companies primarily through structured debt and senior secured loans. CRG works across the spectrum of healthcare products, technologies and services and targets investment sizes ranging between $20 million and $300 million. The firm partners with innovative, commercial-stage healthcare companies that address large, unmet medical needs who are seeking flexible financing solutions with a committed, value-add partner to achieve their growth objectives. CRG is headquartered in Houston, Texas with offices in Boulder, Colorado and New York. For additional information, please visit

Disclosure:This release does not constitute an offer to sell or buy any securities and may not be used or relied upon in connection with any offer or sale of securities. It does not constitute a solicitation of clients and may not be used or relied upon in connection with any solicitation of clients. This release is qualified in its entirety by reference to the offering materials of a specific investment opportunity. Neither the Fund nor CRG makes any representation or warranty, either express or implied, as to the accuracy, completeness or reliability of the information contained in this release. Statements in this release are made as of the date hereof unless stated otherwise herein, and the delivery of this release at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time subsequent to such date. Neither the Fund nor CRG has any obligation to update the information contained in this release, including in the event that any such information becomes inaccurate. No person has been authorized to give any information or to make any representation concerning the matters in this release other than the information explicitly contained in this release, and, if given or made, such information or representation must not be relied upon as having been authorized. CRG and its affiliates reserve the right to modify any of the terms of any offering. 

Certain information contained in this release constitutes "forward-looking statements (as defined in the U.S. private securities litigation reform act of 1995)," which can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "seeks," "plans," "scheduled to," "target," "anticipate," "project," "estimate," "intend," "continue" or "believe" or the negatives thereof or other variations thereon or other comparable terminology. Due to various known or unknown risks and uncertainties, including those described in this release and the offering materials of a specific investment opportunity, actual events or results or the actual performance may differ materially from those reflected or contemplated in such forward-looking statements. As a result, you are cautioned not to place undue reliance on these forward-looking statements. No representation or warranty is made as to future performance or such forward-looking statements. The Fund and CRG expressly disclaim any and all liability relating to or resulting from the use of this release.

Media Contact: Nick Rust
212.279.3115 ext. 252

To view the original version on PR Newswire, visit:



More From BioPortfolio on "CRG Appoints Adam Whitehead as Vice President of Investor Relations"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...